Apomorphine and ropinirole reshape canine emesis decisions

CURRENT BRIEF VERSION: A new wave of discussion around canine emetics is focusing on a practical question for clinics: when should veterinarians reach for apomorphine, and when does ropinirole make more sense? The comparison has gained traction through a recent VETgirl podcast and a growing body of published evidence on ropinirole ophthalmic solution, marketed as Clevor. Ropinirole became the first FDA-approved emetic for dogs in June 2020, offering a topical, injection-free option, while apomorphine remains a widely used extra-label standard in U.S. practice. A recent randomized clinical trial discussed by VETgirl, involving 132 client-owned dogs at two specialty hospitals, adds more real-world context by comparing topical ropinirole with IV apomorphine in dogs presenting after suspected toxin or foreign-body ingestion. Recent studies suggest both drugs are effective, but they differ in speed, route of administration, and adverse-effect profile. (fda.gov)

Why it matters: For veterinary teams handling toxin ingestions or foreign-body exposures, the choice between these agents can shape workflow, patient comfort, and case selection. IV apomorphine appears to induce emesis faster, especially in the first 10 minutes, and the newer clinical-trial discussion highlighted by VETgirl centers on whether ropinirole can deliver similar overall effectiveness with fewer adverse effects in ER patients. Apomorphine still requires in-clinic administration and can contribute to CNS depression. Ropinirole, by contrast, is FDA-approved, easy to administer as eye drops, and may be less likely to worsen CNS depression, though it brings transient ocular irritation and should be avoided in dogs with ocular disease. (pubmed.ncbi.nlm.nih.gov)

What to watch: Expect more discussion around protocol design, including whether ropinirole is best positioned as a first-line option in selected dogs, how clinics use sequential therapy when initial emesis is incomplete, and how antiemetic rescue fits into post-emesis management. Separately, vomiting management more broadly may get a workflow update with Dechra’s newly approved Emeprev injectable maropitant, a bioequivalent antiemetic for dogs and cats that the company says reduces injection pain and does not require refrigeration. (cliniciansbrief.com)